Toxicities by herbal medicines with emphasis to traditional Chinese medicine

Current Drug Metabolism

Volumn 12, Issue 10, 2011, Pages 989-996

  Efferth, Thomas ^a   Kaina, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Herbal medicine; Medicinal plants; Pharmacognosy; Phytotherapy; Toxicology; Traditional Chinese medicine

Indexed keywords

ACETYLSALICYLIC ACID; ACONITINE; ACONITUM EXTRACT; AFLATOXIN; AJOENE; ALLICIN; ANTITHROMBIN III; ARISTOLOCHIA FANGCHI EXTRACT; CADMIUM; CYTOCHROME P450; DIGOXIN; EPHEDRA SINICA EXTRACT; EPHEDRINE; FENFLURAMINE; GARLIC EXTRACT; GINKGOLIDE; GINSENOSIDE RB 2; HERBACEOUS AGENT; HEXACHLOROBENZENE; HYPACONITINE; MESACONITINE; METHYLTESTOSTERONE; OXYTOCIN; PHENACETIN; QUINTOZENE; SALVIA MILTIORRHIZA EXTRACT; SILDENAFIL; THALLIUM; UNINDEXED DRUG; WARFARIN;

ACETYLCHOLINE RELEASE; ACONITUM; AGITATION; ARTICLE; ASTHMA; BLEEDING; CARDIOTOXICITY; CHINESE MEDICINE; CLEMATIS; CONTAMINATION; COUGHING; CYTOTOXICITY; DIABETES MELLITUS; DIARRHEA; EPHEDRA SINICA; GINKGO BILOBA; GINSENG; HAY FEVER; HEADACHE; HEPATITIS; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERTENSION; HYPHEMA; INTOXICATION; MICROORGANISM; NEURALGIA; PAIN; RESPIRATORY TRACT INFECTION; SALVIA MILTIORRHIZA; SEIZURE; SNAKEBITE; STANDARDIZATION; STEPHANIA TETRANDRA; STROKE; TACHYCARDIA; TOXICITY; TRADITIONAL MEDICINE; URINARY EXCRETION; VOMITING;

DRUG CONTAMINATION; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HERBAL MEDICINE; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; PLANTS, MEDICINAL;

EID: 82255195527     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798062328     Document Type: Article

References (121)

1. Barrett, B.; Kiefer, D.; Rabago, D. Assessing the risks and benefits of herbal medicine: An overview of scientific evidence. Altern. Ther. Health Med., 1999, 5, 40-49.
2. Akerele, O. Nature's medicinal bounty: don't throw it away. World Health Forum, 1993, 14, 390-95. (Pubitemid 24010342)
3. Efferth, T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets, 2006, 7, 407-21. (Pubitemid 43744832)
4. Efferth, T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med., 2007, 73, 299-309. (Pubitemid 46910410)
5. Efferth, T.; Fu, Y. J.; Zu, Y. G.; Schwarz, G.; Konkimalla, V. S.; Wink, M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr. Med. Chem., 2007, 14, 2024-32. (Pubitemid 47578160)
6. Efferth, T.; Miyachi, H.; Bartsch, H. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics, 2007, 4, 81-91. (Pubitemid 46632029)
7. Sertel, S.; Plinkert, P. K.; Efferth, T. Natural products derived from traditional Chinese medicine as novel inhibitors of the epidermal growth factor receptor. Comb. Chem. High Throughput Screen, 2010, 13, 849-54.
8. Jiang, M.; Yang, J.; Zhang, C.; Liu, B.; Chan, K.; Cao, H.; Lu, A. Clinical studies with traditional Chinese medicine in the past decade and future research and development. Planta Med., 2010, 76, 2048-64.
9. Feng, Y.; Wang, N.; Zhu, M.; Feng, Y.; Li, H.; Tsao, S. Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Pat. Food Nutr. Agric., 2011, 3, 30-48.
10. Adams, J.; Lui, C. W.; Sibbritt, D.; Broom, A.; Wardle, J.; Homer, C.; Beck, S. Women's use of complementary and alternative medicine during pregnancy: a critical review of the literature. Birth, 2009, 36, 237-45.
11. Parekh, H. S.; Liu, G.; Wie, M. Q. A new dawn for the use of traditional Chinese medicine in cancer therapy. Mol. Cancer, 2009, 8, 21.
12. Olsen, S. A. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup. Ther. Int., 2009, 16, 57-70.
13. Shaw, D. Toxicological risks of Chinese herbs. Planta Med., 2010, 76, 2012-2018.
14. Zeng, Z. P., Jiang, J. G. Analysis of the adverse reactions induced by natural product-derived drugs. Br. J. Pharmacol., 2010, 159, 1374-91.
15. Eisenberg, D. M.; Kessler, R. C.; Foster, C.; Norlock, F. E.; Calkins, D. R.; Debanco, T. L. Unconventional medicine in the United States. Prevalence costs, and patterns of use. New England J. Med., 1993, 328, 246-52. (Pubitemid 23035311)
16. Efferth, T.; Li, P. C.; Konkimalla, V. S.; Kaina, B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med., 2007, 13, 353-61. (Pubitemid 47126989)
17. Polonio, T.; Efferth, T. Leishmaniasis: drug resistance and natural products (review). Int. J. Mol. Med., 2008, 22, 277-86.
18. Wohlfarth, C.; Efferth, T. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol. Sin., 2009, 30, 25-30.
19. Efferth, T. Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. Planta Med., 2010, 76, 1143-54.
20. Ernst, E. The role of complementary and alternative medicine. Brit. Med. J., 2000, 319, 693-96.
21. Kessler, R. C.; Davies, R. B.; Foster, D. F.; Van Rompay, R. I.; Walters, E. E.; Wilkey, S. A.; Kaptchuk, T. J.; Eisenberg, D. M. Longterm trends in the use of complementary and alternative medical therapies in the United States. Ann. Intern. Med., 2001, 135, 262-268. (Pubitemid 32799340)
22. Strader, D. B.; Bacon, B. R.; Lindsay, K. L.; La Breque, D. R.; Morgan, T.; Wright, E. C.; Allen, J.; Khokar, M. F.; Hoofnagle, J. H.; Seeff, L. B. Use of complementary and alternative medicine in patients with liver disease. Am. J. Gastro., 2002, 97, 2391-2397.
23. Flora, K. D.; Rosen, H. R.; Brenner, K. G. The use of neuropathic remedies for chronic liver disease. Am. J. Gastro., 1996, 91, 2654-2655. (Pubitemid 26406346)
24. Eisenberg, D. M.; Davis, R. B.; Ettner, S. L.; Appel, S.; Wilkey, S.; Van Rompay, M.; Kessler, R. C. Trends in alternative medicine use in the United States, 1990-1997. J. Am. Med. Assoc., 1998, 280, 1569-1575.
25. Breevort, P. The U. S. botanical market - an overview. Herbologramm, 1996, 36, 49-57.
26. De Smet, P. A. Herbal remedies. N. Engl. J. Med., 2002, 347, 2046-2056. (Pubitemid 35461662)
27. Jha, V.; Chugh, K. Nephropathy associated with animal, plant and chemical toxins in the tropics. Semin. Nephrol., 2003, 23, 49-65. (Pubitemid 36164469)
28. Eisenberg, D. M.; Kessler, R. C.; Van Rompay, M. I. eta. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann. Intern. Med., 2001, 135, 344-351. (Pubitemid 32823241)
29. Barnes, J.; Mills, S. Y.; Abbot, N. C.; Willoughby, M.; Ernst, E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br. J. Clin. Pharmacol., 1998, 45, 496-500. (Pubitemid 28228730)
30. Villegas, J. F.; Barabe, D. N.; Stein, R. A.; Lazar, E. Adverse effects of herbal treatment of cardiovascular disease: what the physician must know. Heart Dis., 2001, 3, 169-175. (Pubitemid 33131470)
31. Dasgupta, A. Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. Am. J. Clin. Pathol., 2003, 120, 127-37. (Pubitemid 37046380)
32. Chan, K. Some aspects of toxic contaminents in herbal medicines. Chemosphere, 2003, 52, 1361-71. (Pubitemid 41123338)
33. Youns, M.; Hoheisel, J. D.; Efferth, T. Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Med., 2010, 76, 2019-25.
34. Teschke, R.; Qiu, S. X.; Xuan, T. D.; Lebot, V. Kava and Kava Hepatotoxicity: Requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Phytother. Res., 2011, 201. doi: 10.1002/ptr.3464. [Epub ahead of print].
35. Efferth, T. Perspectives for globalized natural medicines. 2011, 9, 1-6.
36. Tzin, V.; Galili, G. New insights into the shikimate and aromatic amino acids biosynthesis pathways in plants. Mol. Plant., 2010, 3, 956-72.
37. Bagnis, C. I.; Deray, G.; Baumelou, A.; Le Quintrec, M.; Vanherwegen, J. L. Herbs and the Kidney. National Kidney Foundation, 2004, 44, 1-11. (Pubitemid 38880921)
38. Vanherwegen, J. L.; Depierreux, M.; Tielemans, C.; Abramowicz, D. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet, 1993, 341, 387-391. (Pubitemid 23048140)
39. Nortier, J. L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med., 2000, 342, 1686-1692. (Pubitemid 30354515)
40. Arlt, V. M. et al. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis, 2002, 17, 265-277. (Pubitemid 34814645)
41. Arlt, V. M. et al. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int. J. Cancer, 2004, 111, 977-980. (Pubitemid 39096251)
42. Zhu, Y-P. Toxicity of the Chinese herb Mu Tong (Aristolochia manshuriensis). What history tells us. Adv. Drug. React. Toxicol., 2002, 21, 171-177. (Pubitemid 36018764)
43. Yuen, S.; Lau-Cam, C. A. Thin layer chromatographic screening procedure for undeclared synthetic drugs in Chinese herbal preparations. J. Chrom., 1985, 329, 107-112. (Pubitemid 15068234)
44. Karunanithy, R.; Sumita, K. R. Undeclared drugs in traditional Chinese anti-rheumatoid medicines. Int. J. Pharm. Practice, 1991, 1, 117-119.
45. Jin, J.; Berry, M. I.; Chan, K. Chinese herbal medicine in the UK. Pharm. J., 1995, 255, R37.
46. Yu, H.; Zhong, S.; Chan, K.; Berry, M. I. Pharmacognostical investigation on traditional Chinese medicinal herbs: identification of four herbs from the UK market. J. Pharm. Pharmacol., 1995, 47, 1129.
47. Yu, H.; Zhong, S.; Berry, M. I.; Chan, K. Pharmacognostical investigation on traditional Chinese medicinal herbs: identification of six herbs from the UK market. J. Pharm. Pharmacol., 1997, 49, 212.
48. Ernst, E.; De Smet, P. A. Adverse effects of complementary therapies. In: Duke; MNG (Ed.), Meyler's Side Effects of Drugs. Amsterdam, Elsevier, 1996.
49. Marcus, D.; Grollman, A. Botanical medicines - The need for new regulations. N. Engl. J. Med., 2002, 347, 2073-2076. (Pubitemid 35461667)
50. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J. Clin. Pharmacol., 1997, 37, 344-350. (Pubitemid 27184660)
51. Product review: Asian and American ginseng (Vol. 2002) [Online]. Available: http://www.consumerlab.com/results/ginseng. html. ConsumerLab.com, LLC, 2002.
52. Wu, W. L. Occurrence and physiological activities of trace elements in traditional Chinese drugs. Zhonghua Yaoxue Zazhi, 1992, 44, 269-280.
53. Wong, M. K.; Tan, P.; Wee, Y. C. Heavy metals in some Chinese herbal plants. Biol. Trace Elem. Res., 1993, 36, 135-142. (Pubitemid 23069648)
54. Ueng, T. H.; Kang, J. J.; Wang, H. W.; Lin, P. C. An overview of the toxicology of commonly used traditional Chinese medicine. Yaowu Shipin Fenxi, 1997, 5, 242-263.
55. Liang, W. L.; Lin, S. W.; Yen, K. Y.; Yang, L. L. Metal element analysis of commercial Chinese herbal medicines. Taiwan Kexue, 1998, 51, 37-56.
56. Au, A. M.; Ko, R.; Boo, F. O.; Hsu, R.; Perez, G.; Yang, Z. Screening methods for drugs and heavy metals in Chinese patent medicines. Bull. Environ. Contam. Toxicol., 2000, 65, 112-119. (Pubitemid 30491027)
57. Wu, M.; Hong, J.; Lin, J.; Yang, C.; Chien, H. Multiple tubular dysfunction induced by mixed Chinese herbal medicines containing cadmium. Nephrol. Dial. Transplant., 1996, 11, 867-870. (Pubitemid 26148263)
58. Koh, H.-L.; Woo, S.-O. Chinese proprietary medicine in Singapore: Regulatory control of toxic heavy metals and undeclared drugs. Drug Safety, 2000, 23, 351-362.
59. Peng, C.; Zheng, T.; Yang, F.; Li, Y. X.; Zhang, D. K. Study of neurotoxic effects and underlying mechanisms of aconitine on cerebral cortex neuron cells. Arch. Pharm. Res., 2009, 32, 1533-43.
60. Lin, C. C.; Phua, D. H.; Deng, J. F.; Yang, C. C. Aconitine intoxication mimicking acute myocardial infarction. Hum. Exp. Toxicol., 2010, [Epub ahead of print].
61. Sun, W. J. Quantitative determination of total alkaloids and aconitine in the root of Aconitum carmichaeli and Aconitum Kusnezoffii [in Chinese]. Chung Yao Tung Pao, 1984, 9, 125-127.
62. Chan, T. Y. K.; Tomlinson, B.; Tse, L. K. K.; Chan, J. C.; Chan, W. W.; Critchley, J. A.. Aconitine poisoning due to Chinese herbal medicines: a review. Vet. Hum. Toxicol., 1994, 36, 452-455. (Pubitemid 24300067)
63. Alibeu, J. P.; Jobert, J. Aconite in homeopathic relief of postoperative pain and agitation in children [in French]. Pediatrie, 1990, 45, 465-466.
64. Guha, S.; Dawn, B.; Dutta, G.; Chakraborty, T.; Pain, S. Bradycardia, reversible panconduction defect and syncope following self-medication. Cardiology, 1999, 91, 268-271. (Pubitemid 29502091)
65. Merchant, H. C.; Choksi, N. D.; Ramamoorthy, K.; Parihar, L. M.; Shikaripurkar, N. K. Aconite poisoning and cardiac arrhythmias: report of 3 cases. Indian J. Med. Sci., 1963, 17, 857-865.
66. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Li, C.; Wang, G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 2007, 29, 687-710. (Pubitemid 350190847)
67. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 2008, 9, 310-222.
68. Wang, B.; Zhou, S. F. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr. Med. Chem., 2009, 16, 4066-4218.
69. Eichhorn, T.; Efferth, T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from traditional Chinese medicine. J. Ethnopharmacol. (in press)
70. Tomlinson, B.; Hu, M.; Lee, V. W. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Mol. Nutr. Food Res., 2008, 52, 799-809.
71. Efferth, T.; Volm, M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther., 2005, 107, 155-176. (Pubitemid 40910039)
72. Fang, H.; Wang, K.; Zhang, J. Transcriptome and proteome analyses of drug interactions with natural products. Curr. Drug Metab., 2008, 9, 1038-1048.
73. Cheng, K. F.; Leung, K. S.; Leung, P. C. Interactions between modern and Chinese, medicinal drugs: a general review. Am. J. Chin. Med., 2003, 2, 163-169. (Pubitemid 41758837)
74. Geller, S. E.; Kronenberg, F. Toward optimal health: the experts discuss the use of botanicals by women. Interview by Jody Godfrey Meisler. J. Women Health (Larchmt.), 2003, 12, 847-852.
75. Huntley A. Drug-herb interactions with herbal medicines for menopause. J. Br. Menopause Soc., 2004, 10, 162-165. (Pubitemid 40057760)
76. Heck, A. M.; DeWitt, B. A.; Lukes, A. L. Potential interactions between alternative therapies and warfarin. Am. J. Health Syst. Pharm., 2000, 57, 1221-1227.
77. Vaes, L. P.; Chyka, P. A. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann. Pharmacother., 2000, 34, 1478-1482.
78. Rosenblatt, M.; Mindel, J. Spontaneous hyphema associated with ingestion of ginkgo biloba extract. N. Engl. J. Med., 1997, 336, 1108-1114.
79. Bourget, S.; Baudrant, M.; Allenet, B.; Calop, J. Oral anticoagulants: a literature review of herb-drug interactions or food-drug interactions]. J. Pharm. Belg., 2007, 62, 69-75. French. (Pubitemid 47528670)
80. Holbrook, A. M.; Pereira, J. A.; Labiris, R.; McDonald, H.; Douketis, J. D.; Crowther, M.; Wells, P. S.. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med., 2005, 165, 1095-1106. (Pubitemid 40720733)
81. Lam, A. Y.; Elmer, G. W.; Mohutsky, M. A. Possible interaction between warfarin and Lycium barbarum L. Ann. Pharmacother., 2001, 35, 1199-1201. (Pubitemid 32959186)
82. Sze, D. M.; Chan, G. C. Supplements for immune enhancement in hematologic malignancies. Hematology Am. Soc. Hematol. Educ. Program., 2009, 313-319.
83. Zhou, L.; Zuo, Z.; Chow, M. S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol., 2005, 45, 1345-1359. (Pubitemid 41643896)
84. Yu, C. M.; Chan, J. C.; Sanderson, J. E. Chinese herbs and warfarin potentiation by 'danshen'. J. Intern. Med., 1997, 241, 337-339. (Pubitemid 27224000)
85. Tam, L. S.; Chan, T. Y.; Leung, W. K.; Critchley, J. A. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Aust. N. Z. J. Med., 1995, 25, 258.
86. Chan, T. Y. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann. Pharmacother., 2001, 35, 501-514.
87. Cheng, B.; Hung, C. T.; Chiu, W. Herbal medicine and anaesthesia. Hong Kong Med. J., 2002, 8, 123-130. (Pubitemid 34297062)
88. Makheja, A. N.; Bailey, J. M. Antiplatelet constituents of garlic and onion. Agents Actions. 1990, 29, 360-363. (Pubitemid 20098466)
89. Srivastava, K. C.; Tyagi, O. D. Effects of a garlic-derived principle (ajoene) on aggregation and arachidonic acid metabolism in human blood platelets. Prostaglandins Leukot. Essent. Fatty Acids., 1993, 49, 587-595. (Pubitemid 23236519)
90. Burnham, B. E. Garlic as a possible risk for postoperative bleeding. Plast. Reconstr. Surg. 1995, 95, 213-216.
91. German, K.; Kuma, U.; Blackford, H. N. Garlic and the risk of TURP bleeding. Br. J. Urol., 1995, 76, 518-523.
92. Coon, J. T.; Ernst, E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf., 2002, 25, 323-344. (Pubitemid 34634271)
93. Liu, C. X.; Xiao, P. G. Recent advances on ginseng research in China. J. Ethnopharmacol., 1992, 36, 27-38.
94. Fugh-Berman, A. Herb-drug interactions. Lancet, 2000, 355, 134-138. (Pubitemid 30068565)
95. Gruenwald, J.; Brendler, T.; Jaenicke, C. PDR for herbal medicines. 1st ed. Montvale: New Medical Economics Company; 1998:826-7.
96. http://medicines.mhra.gov. uk. Accessed June 3rd 2011
97. Almeida, J. C.; Grimsley, E. W. Coma from the health food store: interaction between kava and alprazolam. Ann. Intern. Med., 1996, 125, 940-941.
98. Herr, S. M.; Edzard, E.; Veronica, S. L. Young, eds. Herb-drug interaction handbook. 2nd edn. Nassau NY: Church Street Books, 2002.
99. Nahrstedt, A.; Butterweck, V. Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular). J. Nat. Prod., 2010, 73, 1015-21.
100. Kasper, S.; Gastpar, M.; Müller, W. E.; Volz, H. P.; Dienel, A.; Kieser, M.; Möller, H. J.. Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258, 59-63. (Pubitemid 351208250)
101. Rahimi, R.; Nikfar, S.; Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 118-27.
102. Freeman, M. P.; Fava, M.; Lake, J.; Trivedi, M. H.; Wisner, K. L.; Mischoulon, D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J. Clin. Psychiatry, 2010, 71, 669-81.
103. Linde, K.; Mulwow, C. D.; Berner, M.; Egger, M. St. John's wort for depression. Cochrane Database Syst. Rev., 2005, 2, CD000448.
104. Linde, K.; Ramirez, G.; Mulrow, C. D.; Pauls, A.; Weidenhammer, W.; Melchart, D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. Br. Med. J., 1996, 313, 253-258. (Pubitemid 26254730)
105. Röder, C.; Schaefer, M.; Leucht, S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort. Fortschr. Neurol. Psychiatr., 2004, 72, 330-343. [Article in German] (Pubitemid 38828820)
106. Medical Products Agency: St. John's Wort may influence other medications. Sweden, 2002.
107. Ernst, E. Second thoughts about safety of St. John's wort. Lancet, 1999, 354, 2014-16.
108. Madabushi, R.; Frank, B.; Drewelow, B.; Derendorf, H.; Butterweck, V. Hyperforin in St. John's wort drug interactions. Eur. J. Clin. Pharmacol., 2006, 62, 225-233. (Pubitemid 43357581)
109. Kober, M.; Pohl, K.; Efferth, T. Molecular mechanisms underlying St. John's wort drug interactions. Curr. Drug Metab., 2008, 9, 1027-37.
110. Chen, Z. S.; Nie, Z. W.; Sun, Q. L. [Clinical study in treating intractable ulcerative colitis with traditional Chinese medicine]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 1994, 14, 400-402. [Article in Chinese]
111. Gupta, I.; Parihar, A.; Malhotra, P.; Singh, G. B.; Lüdtke, R.; Safayhi, H.; Ammon, H. P.. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res., 1997, 2, 37-43.
112. Liu, J. P.; Zhang, M.; Wang, W. Y.; Grimsgaard, S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2004, 3, CD003642.
113. Liu, J. P.; Manheimer, E.; Yang, M. Herbal medicines for treating HIV infection and AIDS. Cochrane Database Syst. Rev., 2005, 3, CD003937.
114. Kennedy, J. Herb and supplement use in the US adult population. Clin. Ther. 2005, 27, 1847-58. (Pubitemid 41815236)
115. Hanje, A. J.; Fortune, B.; Song, M.; Hill, D.; McClain, C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr. Clin. Pract. 2006, 21, 255-72.
116. Garrow, D.; Egede, L. E. National patterns and correlates of complementary and alternative medicine use in adults with diabetes. J. Altern. Complement. Med., 2006, 12, 895-902. (Pubitemid 44770982)
117. Kanodia, A. K.; Legedza, A. T.; Davis, R. B.; Eisenberg, D. M.; Phillips, R. S. Perceived benefit of Complementary and Alternative Medicine (CAM) for back pain: a national survey. J. Am. Board Fam. Med., 2010, 23, 354-62.
118. McGuffin, M.; Hobbs, C.; Upton, R. et al. Botanical safety handbook. New York: CXRC Press, 1997.
119. Leung, A. Y. Traditional documentation of Chinese Materia Medica. Toxicol. Pathol., 2006, 34, 319-326.
120. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets, 2011, 12, 122-32.
121. Konkimalla, V. B.; Efferth, T. Evidence-based Chinese medicine for cancer therapy. J. Ethnopharmacol., 2008, 116, 207-10.